ORGANOPlus is a biotechnology company developing patient-derived organ-on-a-chip platforms to build human-relevant disease models connected with standardized Human Validation data and AI-based validation. The company builds platforms reproducing human physiological and pathological microenvironments across disease areas, including gut and oncology, with standardized SOPs and QC processes for reproducible data generation. ORGANOPlus transforms experimental outputs into structured Human Validation datasets and integrates them with multimodal and clinical data to build AI models through cross-validation, enabling reliable validation and prediction. Core platforms include VILLIORGAN™ for gut and microbiome models, CANORGAN™ for tumor microenvironment-based cancer models, and MAXORGAN™ for multi-organ interaction models. Through this integrated Human Validation Infrastructure, ORGANOPlus supports reliable preclinical development, precision medicine, and next-generation drug development.